The American Society of Hematology (ASH) represents more than 17,000 clinicians and scientists across the country committed to the study and treatment of blood and blood-related diseases. ASH members include clinicians who specialize in treating children and adults with SCD and researchers who investigate the causes and potential treatments of SCD manifestations. To learn about how ASH is working towards conquering sickle cell disease, visit www.hematology.org/scd.
SCD is a blood disorder
SCD is an inherited blood disorder that affects red blood cells. Normal red blood cells are round and flexible, which lets them travel through small blood vessels to deliver oxygen to all parts of the body.
In the United States, it is estimated that: 
And creates painful complications
The sickle-shaped red blood cells break apart easily, clump together, and stick to the walls of blood vessels, blocking the flow of blood which can cause a range of serious health issues.
It causes misshapen blood cells
SCD causes red blood cells to form into a crescent shape, like a sickle. Only 2 treatment options:
Treatment value 75% D A T A C O L L E C T I O N O P P O R T U N I T I E S
Hydroxyurea and L-glutamine are currently the only FDA-approved medications used to treat SCD. L-glutamine has been approved to treat patients 5 years and older.
90%
of people with SCD today live well into adulthood, which poses new issues and challenges.
5
Bone marrow transplantation is a cure for some individuals with SCD but may not be an option for everyone.
Only 1 in 3 children with SCD receive appropriate monitoring for stroke by age 2.
3
Children not treated with hydroxyurea accrue over $500,000 more in health care costs than those who receive this treatment.
4
Data collection programs are necessary to understand the health outcomes and health care utilization patterns of individuals with SCD and to build cost-e ective practices to improve and extend these patients' lives.
Currently, the CDC collects data on the incidence and treatment progress of individuals through funding provided by the CDC Foundation. As a result, data collection programs only occur in two states: California and Georgia. The Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018 authorizes an expansion of CDC's data collection e orts. Newly authorized data collection grants will need funding in 2020 and beyond.
Increased funding
for regional grants improves care by providing genetic counseling and testing, training health professionals, and expanding continuity of care.
New, dedicated funding
to allow for the expansion of existing data collection programs across the U.S. SCD population increases evidence for public health programs to establish cost-e ective practices that improve and extend the lives of people with SCD.
Development of education
and outreach e orts for the general public and medical community increases overall awareness of SCD and knowledge of health outcomes, helps audiences understand the e ects of medical interventions, and informs best practices.
